These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 9096194)
1. Antimicrobial susceptibilities of blood culture isolates obtained before and after the introduction of ciprofloxacin. Pieroni P; Goodfellow J; Reesor L; Louie M; Simor AE J Antimicrob Chemother; 1997 Mar; 39(3):419-22. PubMed ID: 9096194 [TBL] [Abstract][Full Text] [Related]
2. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Shigeta S; Yamaguti O; Ishibashi K; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Muratani T; Naito S; Egashira T; Konishi T; Kohno S; Hirakata Y; Kondo A; Matsuda J; Nakano M Jpn J Antibiot; 2006 Jun; 59(3):177-200. PubMed ID: 16913404 [TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test. Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053 [TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin. Aktaş Z; Gönüllü N; Salcioğlu M; Bal C; Anğ O Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698 [TBL] [Abstract][Full Text] [Related]
5. In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital. Tantisiriwat W; Linasmita P J Med Assoc Thai; 2017 Apr; 100(4):469-78. PubMed ID: 29912484 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates. López-Brea M; Prieto N; Domingo D; de las Cuevas C; Sánchez I; Alarcón T Int J Antimicrob Agents; 1999 Jun; 12(1):33-9. PubMed ID: 10389645 [TBL] [Abstract][Full Text] [Related]
7. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)]. Zarakolu P; Hasçelik G; Unal S Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Karlowsky JA; Lagacé-Wiens PR; Simner PJ; DeCorby MR; Adam HJ; Walkty A; Hoban DJ; Zhanel GG Antimicrob Agents Chemother; 2011 Jul; 55(7):3169-75. PubMed ID: 21537027 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates. Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230 [TBL] [Abstract][Full Text] [Related]
10. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria]. Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920 [TBL] [Abstract][Full Text] [Related]
11. Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases. Ishikawa K; Hamasuna R; Uehara S; Yasuda M; Yamamoto S; Hayami H; Takahashi S; Matsumoto T; Minamitani S; Kadota J; Iwata S; Kaku M; Watanabe A; Sunakawa K; Sato J; Hanaki H; Tsukamoto T; Kiyota H; Egawa S; Deguchi T; Matsumoto M; Tanaka K; Arakawa S; Fujisawa M; Kumon H; Kobayashi K; Matsubara A; Wakeda H; Amemoto Y; Onodera S; Goto H; Komeda H; Yamashita M; Takenaka T; Fujimoto Y; Tsugawa M; Takahashi Y; Maeda H; Onishi H; Ishitoya S; Nishimura K; Mitsumori K; Ito T; Togo Y; Nakamura I; Ito N; Kanamaru S; Hirose T; Muranaka T; Yamada D; Ishihara S; Oka H; Inatomi H; Matsui T; Kobuke M; Kunishima Y; Kimura T; Ichikawa T; Kagara I; Matsukawa M; Takahashi K; Mita K; Kato M; Okumura K; Kawanishi H; Hashimura T; Aoyama T; Shigeta M; Koda S; Taguchi K; Matsuda Y J Infect Chemother; 2015 Sep; 21(9):623-33. PubMed ID: 26166322 [TBL] [Abstract][Full Text] [Related]
12. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. Karlowsky JA; Kelly LJ; Thornsberry C; Jones ME; Evangelista AT; Critchley IA; Sahm DF Int J Antimicrob Agents; 2002 Jan; 19(1):21-31. PubMed ID: 11814764 [TBL] [Abstract][Full Text] [Related]
13. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates. Rubinstein E; Mark Z; Samra Y; Alkan M; Berger S Chemioterapia; 1986 Apr; 5(2):75-82. PubMed ID: 2939966 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976 [TBL] [Abstract][Full Text] [Related]
16. [Comparison between the activity of 2 amino-glycoside antibiotics, tobramycin and gentamicin on gram negative bacteria in vitro]. De Rosa F; Tassi C; Stagni GR Ann Sclavo; 1974; 16(1):65-72. PubMed ID: 4214247 [No Abstract] [Full Text] [Related]
17. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005]. Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265 [TBL] [Abstract][Full Text] [Related]
18. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates. Ismaeel NA; Tayeb OS Microbios; 1993; 74(300):147-54. PubMed ID: 8396196 [TBL] [Abstract][Full Text] [Related]
19. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. Barry AL; Fuchs PC J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012 [TBL] [Abstract][Full Text] [Related]
20. Susceptibility of corneal and conjunctival pathogens to ciprofloxacin. Knauf HP; Silvany R; Southern PM; Risser RC; Wilson SE Cornea; 1996 Jan; 15(1):66-71. PubMed ID: 8907383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]